Lorundrostat (MT-4129) is a highly selective inhibitor of CYP11B2 (aldosterone synthase), with inhibition constant (Ki) values of 1.27 nM for hCYP11B2 and 475 nM for hCYP11B1. It demonstrates potential as a safe and effective treatment for aldosterone-dependent uncontrolled hypertension, including cases of treatment-resistant hypertension.